Welcome to our dedicated page for Apyx Medical news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical stock.
Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Apyx Medical (NASDAQ:APYX) said management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 in Snowbird, Utah.
Investors seeking meetings should contact their BTIG representatives. The company highlighted its Renuvion, J-Plasma, and FDA-cleared AYON Body Contouring System and noted more than 90 supporting clinical documents.
Apyx Medical (Nasdaq: APYX) reported preliminary, unaudited revenue for Q4 and full year 2025. Q4 2025 total revenue is expected to be approximately $19.0–$19.2M (+~34% YoY), driven by Surgical Aesthetics of $16.6–$16.8M (+~38% YoY) and OEM revenue of ~$2.4M (+~13% YoY). Apyx cited a U.S. Surgical Aesthetics increase of ~51% following the AYON commercial launch. For full year 2025, total revenue is expected at $52.7–$52.9M (+~10% YoY), Surgical Aesthetics $45.2–$45.4M (+~17% YoY), and OEM ~$7.5M (−21% YoY). The company will release audited results in March 2026; figures are preliminary and subject to closing and audit procedures.
Apyx Medical (Nasdaq: APYX) announced MFDS approval and the commercial launch of the Apyx One console and single-use handpieces for cosmetic surgical procedures in South Korea.
The company plans to begin shipping to fill initial orders starting in Q4 2025. Apyx One combines Renuvion technology with monopolar and bipolar energy and features adaptive touch screens, procedural presets, energy quantification, and an advanced gas-monitoring system.
Management cited South Korea’s cosmetic surgery market estimate of $1.7 billion in 2024 and a projected increase to $3.9 billion by 2033, and noted increased demand tied to GLP-1 weight-loss drug use and subsequent body-contouring needs.
Apyx Medical (Nasdaq: APYX) priced an underwritten public offering of 2,762,431 shares of common stock at $3.62 per share, representing gross proceeds of approximately $10.0 million. The company granted the underwriter a 45-day option to purchase up to an additional 414,365 shares at the public offering price less underwriting discounts.
The offering is expected to close on or about November 19, 2025, subject to customary closing conditions. Net proceeds are intended for working capital and general corporate purposes. Lucid Capital Markets is sole book-runner. The offering is made under a shelf registration statement declared effective December 2, 2022.
Apyx Medical (Nasdaq: APYX) announced on November 17, 2025 that it has commenced a proposed underwritten public offering of common stock or common stock equivalents, subject to market conditions.
Lucid Capital Markets is sole book-running manager. The offering will be made from a shelf registration on Form S-3 (File No. 333-268532) declared effective December 2, 2022; a preliminary prospectus supplement and prospectus will be filed with the SEC and posted at www.sec.gov when available. The company cautioned there is no assurance the offering will be completed on the anticipated terms.
Company products include Renuvion, AYON Body Contouring System (FDA-cleared), and J-Plasma, supported by more than 90 clinical documents.
Apyx Medical (NASDAQ:APYX) reported Q3 2025 total revenue $12.9M, up from $11.5M a year earlier, driven by Surgical Aesthetics $11.1M (+19%) and domestic sales rising over 30%.
Gross margin improved to 64.4%. Net loss attributable to stockholders narrowed to $2.0M (Q3 2024: $4.7M). Adjusted EBITDA loss fell to $0.1M from $2.4M.
The company launched commercial U.S. sales of the AYON Body Contouring System in September 2025, received 510(k) clearance in May 2025, and filed an additional 510(k) in October 2025 to add power liposuction labeling. Full-year 2025 revenue guidance was raised to $50.5M–$52.5M.
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend investor meetings in New York in November 2025.
They will participate in 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at Sheraton NY Times Square, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at Westin NY Grand Central.
Investors seeking meetings should contact their Craig Hallum or Canaccord Genuity representatives. The release also restates the company’s Helium Plasma Platform products (Renuvion, AYON Body Contouring System, J-Plasma), notes >90 clinical documents supporting Renuvion and J-Plasma, and describes AYON as FDA-cleared.
Apyx Medical (NASDAQ: APYX) announced it will release its third quarter fiscal 2025 financial results before markets open on Thursday, November 6, 2025.
Management will host a conference call at 8:00 a.m. Eastern Time on November 6 to discuss results and conduct a Q&A. Dial-in numbers are 800-717-1738 (U.S.) or 646-307-1865 (international) with access code 73607. A live webcast will be available and archived in the company’s Investor Relations section.
Contact for investors is Jeremy Feffer at LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). The company sells helium plasma and RF products under the Renuvion, AYON Body Contouring System, and J-Plasma brands, supported by more than 90 clinical publications.
Apyx Medical (NASDAQ: APYX) announced on October 13, 2025 that it submitted a new FDA 510(k) premarket notification to expand the label of the AYON Body Contouring System to include power liposuction.
The company began a nationwide commercial launch of AYON in September 2025 and said that, if cleared, the power liposuction function could be activated in systems already installed at U.S. surgical centers.
A virtual key opinion leader event on October 14, 2025 will discuss the commercial launch.
Apyx Medical (NASDAQ:APYX) announced a virtual Key Opinion Leader (KOL) event scheduled for October 14, 2025, at 12:00 PM ET. The event will feature Dr. Paul Vanek, Jr., FACS, alongside company management, to discuss the commercial launch of the AYON Body Contouring System™.
The AYON system is the first FDA-cleared all-in-one platform for aesthetic surgical suites, incorporating the company's proprietary Renuvion technology. The system combines fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, designed to streamline procedures and enhance patient outcomes. The event will include formal presentations followed by a Q&A session.